Abbott and GSK to Collaborate on Molecular Diagnostic Test
- Details
- Category: Abbott
Abbott has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen. GSK's MAGE-A3 ASCI (Antigen Specific Cancer Immunotherapy) candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical study MAGRIT, the largest lung cancer treatment study ever conducted.
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effientâ¢
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Effient™(prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).
Bayer acquires exclusive rights to Bioton's insulin SciLin®
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton's Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin® in China.
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
AstraZeneca to Advance AZD3480 in ADHD
- Details
- Category: AstraZeneca
AstraZeneca plans to conduct further development of AZD3480 by initiating Phase IIb studies in attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept. AstraZeneca also plans to continue development of AZD1446 (TC-6683) for Alzheimer's disease. AZD1446 is currently in Phase 1 and was discovered in the ongoing AstraZeneca-Targacept research collaboration.
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US
- Details
- Category: Bayer
Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new estradiol-based oral
contraceptive (estradiol valerate/dienogest). It seeks approval for the indications oral contraception and treatment of heavy and/or prolonged menstrual bleeding. The new product with an estradiol valerate/dienogest combination is the first in a new class of oral contraceptives to deliver estradiol, the estrogen identical to the one produced by the female body.
Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies
- Details
- Category: Lundbeck
Through the acquisition of the Aarhus-based biotech company NeuronIcon, Lundbeck will gain ownership of technologies that may lead to a breakthrough in the treatment of brain damage following strokes or similar events. The acquisition is the result of Lundbeck's intensified collaboration with universities in Denmark and abroad.
More Pharma News ...
- Top 10 Tips for Staying Healthy When Money is Tight
- Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- GSK further extends its product portfolio in the Middle East and North Africa
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Bayer files patent infringement lawsuit against Teva